Causes & What We Know/August 26, 2026/3 min read

Beyond Blood Tests: How Scientists Are Using Multiple Layers of Data to Better Predict Type 1 Diabetes Risk

Traditional markers like genes and autoantibodies don't tell the whole story about who will develop Type 1 diabetes or how fast it will progress. New research explores how combining information from multiple biological systems could improve risk prediction.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

Current risk prediction tools for Type 1 diabetes rely mainly on genetic markers, autoantibodies, and blood sugar levels—but these alone often aren't accurate enough to identify people at highest risk or predict how quickly the disease will develop
Multi-omics is an approach that looks at many different biological systems at once: genes, gene activity, proteins, metabolites, epigenetics, and gut bacteria, to build a more complete picture
Scientists believe combining data from all these biological layers could help identify which people are about to progress to Type 1 diabetes and support personalized prevention strategies
Artificial intelligence tools are being developed to help make sense of the complex patterns in multi-omics data and make predictions
Major challenges remain in validating these new approaches and translating them into tools that patients and doctors can actually use in clinical care

The Limits of Today's Risk Prediction

Doctors currently identify Type 1 diabetes risk using three main types of information: genetic markers that show inherited susceptibility, autoantibodies that signal the immune system is attacking the pancreas, and markers of how well the body is controlling blood sugar. These biomarkers are valuable and remain essential to clinical care today.

However, when used alone, they often fall short. They cannot reliably distinguish who among at-risk individuals will actually develop diabetes and when, nor can they accurately predict how fast the disease will progress from person to person. This means clinicians lack the precision needed to identify people in immediate danger or to tailor prevention strategies to individual needs.

Type 1 Diabetes Is More Complex Than One Test Can Show

Type 1 diabetes develops through the interaction of genes, environmental exposures, and immune system dysfunction. The disease affects multiple biological systems in ways that traditional blood tests cannot fully capture.

To understand this complexity, researchers are turning to multi-omics—a strategy that examines several layers of biological information simultaneously. These layers include genomics (the DNA sequence itself), transcriptomics (which genes are turned on or off), proteomics (the proteins being produced), metabolomics (the small molecules involved in metabolism), epigenomics (chemical tags on DNA that control gene activity), and the microbiome (bacteria in the gut). Each layer provides different clues about diabetes risk and progression.

How Multi-Omics Could Improve Prediction

By integrating information from all these biological systems, scientists hope to build a much more accurate picture of who is at highest risk, who is about to progress to Type 1 diabetes, and whose disease trajectory will be different from others. This precision could enable individualized prevention approaches tailored to each person's unique biology.

The research also focuses on identifying stage-specific biomarkers—different markers that matter at different points in the disease process—and developing artificial intelligence models to detect meaningful patterns across vast amounts of biological data that humans could not analyze manually.

From Lab Discovery to Real-World Use

While multi-omics integration shows promise, significant work remains. Researchers must validate these new biomarkers rigorously, ensure the data frameworks work reliably, and then translate discoveries into practical tools for clinics and patients. These challenges—technical, scientific, and logistical—must be solved before multi-omics approaches can transform how Type 1 diabetes risk is assessed in everyday care.

The field is moving in an evidence-based direction, with researchers carefully evaluating whether integrated multi-omics can deliver on its potential to identify individuals at imminent risk and support more personalized prevention strategies.

Evidence label

Source: Frontiers in immunology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.